Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

Mardi Dier Biography and Net Worth

CFO of Ultragenyx Pharmaceutical

Ms. Dier joined Ultragenyx on October 12, 2020 and is responsible for leading the corporate finance, strategy, investor relations, corporate communications and information technology functions.

She joined Ultragenyx from Portola Pharmaceuticals (acquired by Alexion), where she served as Chief Financial Officer for 14 years and, most recently, also as Chief Business Officer. Over the course of her time at Portola she oversaw a wide range of functions including global supply chain. Prior to Portola, she served as Vice President of Investor Relations at Chiron Corporation until its acquisition by Novartis. Earlier in her career, she worked as an investment banker at Prudential Securities covering bio pharma, and prior to that was in the audit department of KPMG Peat Marwick. Ms. Dier serves on the Board of Directors of ORIC Pharmaceuticals, Prelude Therapeutics, and Synthakine, Inc.

She holds a B.S. in biology from Stanford University and an M.B.A. from the Anderson School at the University of California, Los Angeles.

Ms. Dier has been recognized twice as one of the most influential women in Bay Area business by the San Francisco Business Times (2013, 2019), and was a finalist for its Bay Area CFO of the Year Award (2013).

What is Mardi Dier's net worth?: The estimated net worth of Mardi Dier is at least $245,686.32 as of May 9th, 2023. Ms. Dier owns 5,556 shares of Ultragenyx Pharmaceutical stock worth more than $245,686 as of December 21st. This net worth estimate does not reflect any other assets that Ms. Dier may own. Learn More about Mardi Dier's net worth.
How do I contact Mardi Dier?: The corporate mailing address for Ms. Dier and other Ultragenyx Pharmaceutical executives is 60 Leveroni Court, Novato CA, 94949. Ultragenyx Pharmaceutical can also be reached via phone at (415) 483-8800 and via email at [email protected]. Learn More on Mardi Dier's contact information.
Has Mardi Dier been buying or selling shares of Ultragenyx Pharmaceutical?: Mardi Dier has not been actively trading shares of Ultragenyx Pharmaceutical during the last ninety days. Most recently, Mardi Dier sold 1,629 shares of the business's stock in a transaction on Friday, October 14th. The shares were sold at an average price of $40.16, for a transaction totalling $65,420.64. Following the completion of the sale, the chief financial officer now directly owns 66,695 shares of the company's stock, valued at $2,678,471.20. Learn More on Mardi Dier's trading history.
Who are Ultragenyx Pharmaceutical's active insiders?: Ultragenyx Pharmaceutical's insider roster includes William Aliski (Director), Camille Bedrosian (EVP), Eric Crombez (Chief Medical Officer and EVP), Mardi Dier (CFO), Matthew Fust (Director), Erik Harris (EVP), Howard Horn (CFO and EVP, Corporate Strategy), Dennis Huang (EVP), Theodore Huizenga (CAO), Emil Kakkis (CEO), Thomas Kassberg (EVP), Karah Parschauer (EVP), John Pinion (Insider), Corsee Sanders (Director), Shalini Sharp (CFO), and Clay Siegall (Director). Learn More on Ultragenyx Pharmaceutical's active insiders.
Are insiders buying or selling shares of Ultragenyx Pharmaceutical?: During the last twelve months, insiders at the biopharmaceutical company sold shares 14 times. They sold a total of 100,072 shares worth more than $5,115,593.08. The most recent insider tranaction occured on December, 10th when CEO Emil D Kakkis sold 8,273 shares worth more than $413,650.00. Insiders at Ultragenyx Pharmaceutical own 5.8% of the company. Learn More about insider trades at Ultragenyx Pharmaceutical.
Information on this page was last updated on 12/10/2024.

Mardi Dier Insider Trading History at Ultragenyx Pharmaceutical

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/14/2022	Sell	1,629	$40.16	$65,420.64	66,695
10/12/2022	Sell	3,484	$38.22	$133,158.48	68,324
10/14/2021	Sell	3,261	$81.16	$264,662.76
10/12/2021	Sell	3,477	$82.79	$287,860.83

Mardi Dier Buying and Selling Activity at Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Company Overview

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

Today's Range

Now: $44.22

$42.85

$44.45

50 Day Range

MA: $49.53

$42.94

$57.70

2 Week Range

Now: $44.22

$37.02

$60.37

Volume

1,707,822 shs

Average Volume

782,100 shs

Market Capitalization

$4.08 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.56